15.61
+8.33%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Erasca
From its filings with the US Securities and Exchange Commission
Erasca is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ERAS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $124.5m. At that date it held total assets of $396.2m and shareholders' equity of $325.2m.
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. Our focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment. Our pipeline enables us to pursue a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Jul 2021
- Employees
- 103
- Website
- erasca.com ↗
- Head office
- 3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Jonathan LimChairman of the Board, Chief Executive Officer, Co-Founder, since 2019$3.9m
- Dr. David ChackoChief Financial Officer and Chief Business Officer$1.9m
- Dr. Michael VarneyDirector, Chair of Research and Development and Scientific Advisory Board member, since 2020$175,459
- Mr. Ebun GarnerGeneral Counsel, Corporate Secretary$2.0m
- Dr. Shannon MorrisChief Medical Officer$1.6m
- Dr. James BristolLead Independent Director$179,095
- Mr. Alexander CasdinIndependent Director$146,909
- Dr. Julie HambletonIndependent Director$138,366
- Dr. Valerie Harding-StartIndependent Director$144,689
- Dr. Jean LiuIndependent Director$138,585
- Dr. Pratik MultaniIndependent Director$134,700
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 35
- Social
- 89
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Erasca employs 103 staff members to support its clinical stage precision oncology research efforts.
- The company has assembled a pipeline with 12 disclosed modality-agnostic programs for RAS/MAPK cancers.
- Naporafenib is the lead product candidate designed as a reversible pan-RAF kinase inhibitor.
Weaknesses
- The firm currently employs 129 full-time employees, which differs from the stated 103 count.
- Seven discovery-stage programs lack clinical data compared to the five clinical-stage programs available.
- The company went IPO on 15 July 2021, indicating a relatively short public market history.
Opportunities
- Targeting RAS directly offers potential therapies for cancers driven by the RAS/MAPK pathway.
- Developing a CNS-penetrant KRAS G12C inhibitor addresses unmet needs in central nervous system cancers.
- Commercializing therapies for RAS/MAPK pathway-driven cancers expands the company's presence in the Health Care sector.
Threats
- Competitors in the Health Care sector may develop superior inhibitors for the RAS/MAPK pathway.
- Regulatory hurdles for the five clinical-stage programs could delay the commercialization of new therapies.
- Market volatility following the 15 July 2021 IPO listing date may impact investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.